This is consistent with the facts that (1) an IAP antagonist alone, which effectively degrades IAP proteins, does not kill cancer [16], and (2) the endogenous TNF levels are too low in the mice and do not efficiently trigger cancer cell apoptosis when IAP proteins are degraded by an IAP antagonist (Fig. 1). The gene discussed is TNF; the disease is cancer.